Results 21 to 30 of about 49,882 (187)

Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells

Haematologica, 2008
The α4β1 integrin very late activation antigen-4 (VLA-4) is an α4 (CD49d)/β1 (CD29) heterodimer. It plays a key role in the adhesion of both hematopoietic progenitor cells and leukemic blast cells to bone marrow stromal cells which express the vascular ...
Ulrich Mahlknecht, Christiane Schönbein
doaj   +1 more source

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

Haematologica, 2013
Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion, Anat Gafter-Gvili, Liat Vidal, Avi Leader, Ron Ram, Adi Shacham-Abulafia, Mical Paul, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani   +9 more
doaj   +1 more source

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia

Haematologica, 2013
Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia.
Alan H. Shih, Stephen S. Chung, Emily K. Dolezal, Su-Jiang Zhang, Omar I. Abdel-Wahab, Christopher Y. Park, Stephen D. Nimer, Ross L. Levine, Virginia M. Klimek   +8 more
doaj   +1 more source

Chloroma of the testis in a patient with a history of acute myeloid leukemia

Journal of Research in Medical Sciences, 2017
Chloroma, or granulocytic sarcoma, is a rare extramedullary solid hematologic cancer, found concomitant with acute myeloid leukemia. It is infrequently associated with other myeloproliferative disorders or chronic myelogenous leukemia.
Mohammad Hossein Sanei, Matin Shariati
doaj   +1 more source

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib

Clinical Case Reports, 2022
Patients with chronic myelogenous leukemia (CML) harboring the T315I mutation who progress to blast phase CML while on ponatinib may be successfully treated with asciminib monotherapy following induction therapy with cytotoxic chemotherapy.
Sarah Tomassetti, Jennifer Lee, Xin Qing
doaj   +1 more source

Stafib‐2‐CR: an Improved Nanomolar and Selective Inhibitor of the Transcription Factor STAT5b Developed by Conformational Restriction of Stafib‐2

Chemistry – A European Journal, EarlyView.
Conformational restriction strategies to increase the activity and selectivity of the STAT5b inhibitor Stafib‐2 are presented. The best conformationally restricted inhibitor Stafib‐2‐CR has threefold higher activity against STAT5b than Stafib‐2. A cell‐permeable prodrug of Stafib‐2‐CR inhibits phosphorylation of STAT5b in cultured human leukemia cells ...
Theresa Münzel, Angela Berg, Christoph Protzel, Sylvie Schäfer, Alexander Jensen‐Feinhals, Thorsten Berg   +5 more
wiley   +1 more source

Myeloid Blast Crisis in A 15 Years Adolescent Under Treatment for CML

Journal of College of Medical Sciences-Nepal
Background Chronic myeloid leukemia is relatively a rare haematological malignancy to present during childhood. CML is classically staged into three progressive phases - chronic, accelerated, and blastic.
Isha Bhandari, Krishna Sagar Sharma, Niva Tiwari, Sudhir Adhikari, Ram Krishna Yadav   +4 more
doaj   +1 more source

A New Case of dic(1;15)(p11;p11) in AML M1: Apropos of a Case and a Review of the Literature

Case Reports in Genetics, 2013
Acute myelogenous leukemia (AML) develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. Specific cytogenetic abnormalities have been identified by karyotype analysis in AML. One of the rare chromosomal abnormalities
Deniz Gören Şahin, Beyhan Durak, Eren Gündüz, Sevilhan Artan, Olga Meltem Akay   +4 more
doaj   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy

Epilepsia, EarlyView.
Abstract Objective Current pharmacotherapy for temporal lobe epilepsy (TLE) is limited to symptomatic treatment and leaves approximately one third of patients with inadequate seizure control. Discovering disease‐modifying targets is an unmet clinical need. We have previously identified senescent cells (SCs) as one such target. Many drugs that eliminate
David J. McFall, Abbas I. Hussain, Michelle Cho, Patrick A. Forcelli   +3 more
wiley   +1 more source